Diabetic ketoacidosis induced by single dose of pembrolizumab

LAUR Repository

Show simple item record

dc.contributor.author Maamari, Julian
dc.contributor.author Yeung, Sai-Ching J.
dc.contributor.author Chaftari, Patrick S.
dc.date.accessioned 2019-09-12T09:18:44Z
dc.date.available 2019-09-12T09:18:44Z
dc.date.copyright 2019 en_US
dc.date.issued 2019-09-12
dc.identifier.issn 1532-8171 en_US
dc.identifier.uri http://hdl.handle.net/10725/11295
dc.description.abstract Immune checkpoint inhibitors are a new class of anticancer drugs recently approved by the US Food and Drug Administration (FDA) for the treatment of various malignancies. Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein-1 (PD-1) receptor and blocks its interaction with programmed cell death ligand-1 (PD-L1) and programmed cell death ligand-2 (PD-L2). Pembrolizumab was first approved by the FDA in 2014 for the treatment of advanced melanoma and is currently approved for use in non-small cell lung cancer and several other neoplasms. Immune checkpoint inhibitors such as pembrolizumab have been reported to induce immune-mediated side effects, including type 1 diabetes mellitus in very rare cases (0.1% in clinical trials). Here,we report the case of a womanwith no known history of diabetes who presented to our emergency department in a state of diabetic ketoacidosis within 3 weeks of receiving only a single dose of pembrolizumab therapy, and without any previous exposure to immunotherapy. This case of abrupt adultonset type 1 diabetes mellitus is an example of the undesirable side effects that can emerge after only a brief exposure to an immune checkpoint inhibitor. Close monitoring of patients receiving immune checkpoint inhibitors is warranted for the early diagnosis and management of imminent and potentially life-threatening complications. en_US
dc.language.iso en en_US
dc.title Diabetic ketoacidosis induced by single dose of pembrolizumab en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 201400801 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal American Journal of Emergency Medicine en_US
dc.journal.volume 37 en_US
dc.journal.issue 2 en_US
dc.article.pages 376.e1-376.e2 en_US
dc.identifier.doi https://doi.org/10.1016/j.ajem.2018.10.040 en_US
dc.identifier.ctation Maamari, J., Yeung, S. C. J., & Chaftari, P. S. (2019). Diabetic ketoacidosis induced by a single dose of pembrolizumab. The American journal of emergency medicine, 37(2), 376-e1. en_US
dc.author.email julian.maamari@lau.edu en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url https://www.sciencedirect.com/science/article/pii/S0735675718308544 en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account